Skip to main content
Year archive

Vivesto — 2018 filings

All 96 regulatory filings released by Vivesto (VIVE) in 2018, sourced directly from the official regulator.

96 Filings
2018 Period
2018 filings (96)
Filing Released Lang
Clarification from the Board of Directors and Management of Oasmia Pharmaceutical AB (publ), “Oasmia” due to Per Arwidsson’s and Arwidsro Investment AB’s request for convening an Extraordinary General
Legal Proceedings Report
2018-12-17 English
Tydliggörande från styrelse och ledning i Oasmia Pharmaceutical AB (publ), ”Oasmia”, med anledning av Per Arwidssons och Arwidsro Investment AB:s begäran om en extra bolagsstämma
Regulatory Filings
2018-12-17 Swedish
Clarification from the Board of Directors and Management of Oasmia Pharmaceutical AB (publ), “Oasmia” due to Per Arwidsson’s and Arwidsro Investment AB’s request for convening an Extraordinary General
Legal Proceedings Report
2018-12-17 English
NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL)
AGM Information
2018-12-14 English
NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL)
AGM Information
2018-12-14 English
KALLELSE TILL EXTRA BOLAGSSTÄMMA I OASMIA PHARMACEUTICAL AB (PUBL)
AGM Information
2018-12-14 Swedish
Major Shareholding Notification 2018
Major Shareholding Notification
2018-12-05 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-12-04 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-12-03 English
Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)
Share Issue/Capital Change
2018-11-30 English
Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2018-11-30 English
Ändring av antalet aktier och röster i Oasmia Pharmaceutical AB (publ)
Share Issue/Capital Change
2018-11-30 Swedish
Oasmia Pharmaceutical AB (publ) Interim report for the period May – October 2018
Interim / Quarterly Report H1 2019
2018-11-30 English
Interim / Quarterly Report 2018
Interim / Quarterly Report Q2 2018
2018-11-30 Swedish
Earnings Release 2019
Earnings Release H1 2019
2018-11-30 English
Oasmia Pharmaceutical AB announces new agreement with Baxter Oncology GmbH for global commercial manufacturing of Apealea®
M&A Activity
2018-11-29 English
Oasmia Pharmaceutical har tecknat ett nytt avtal med Baxter Oncology GmbH för global kommersiell produktion av Apealea®
M&A Activity
2018-11-29 Swedish
Oasmia Pharmaceutical AB announces new agreement with Baxter Oncology GmbH for global commercial manufacturing of Apealea®
M&A Activity
2018-11-29 English
Oasmia intends to issue notice to an extraordinary general meeting at the request of a shareholder and announces that it is subject to legal proceedings with a major shareholder concerning the company
Legal Proceedings Report
2018-11-28 English
Oasmia intends to issue notice to an extraordinary general meeting at the request of a shareholder and announces that it is subject to legal proceedings with a major shareholder concerning the company
Legal Proceedings Report
2018-11-28 English
Oasmia avser att kalla till extra bolagsstämma efter begäran av en av de större aktieägarna i bolaget, som utan grund hävdar rätt till teckningsoptioner 2018/2019
Regulatory Filings
2018-11-28 Swedish
Oasmia Pharmaceutical Receives Approval from European Commission for Apealea® (paclitaxel micellar) in the European Union
Earnings Release FY 2018
2018-11-22 English
Oasmia Pharmaceutical Receives Approval from European Commission for Apealea® (paclitaxel micellar) in the European Union
Regulatory Filings
2018-11-22 English
Oasmia Pharmaceutical AB får godkännande av Europeiska kommissionen för Apealea® (paklitaxel micellär)
Regulatory Filings
2018-11-22 Swedish
New U.S. patent related to Oasmia Pharmaceutical’s nanotechnology platform XR17 has been granted
Regulatory Filings
2018-11-20 English
New U.S. patent related to Oasmia Pharmaceutical’s nanotechnology platform XR17 has been granted
Regulatory Filings
2018-11-20 English
Nytt USA patent avseende Oasmia Pharmaceuticals nanoteknologiska plattform XR17 har beviljats
Regulatory Filings
2018-11-20 Swedish
Major Shareholding Notification 2018
Major Shareholding Notification
2018-11-06 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-11-05 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-11-02 English
Oasmia completes a private placement of new convertible instruments in the amount SEK 80 million
Share Issue/Capital Change
2018-11-01 English
Oasmia genomför emission av konvertibler om 80 miljoner kronor
Capital/Financing Update
2018-11-01 Swedish
Oasmia completes a private placement of new convertible instruments in the amount SEK 80 million
Capital/Financing Update
2018-11-01 English
Ändring av antalet aktier och röster i Oasmia Pharmaceutical AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2018-10-31 Swedish
Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)
Share Issue/Capital Change
2018-10-31 English
Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)
Share Issue/Capital Change
2018-10-31 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-10-04 English
Oasmia Presents Positive Efficacy and Safety Data for Doxophos Vet in Treatment of Naïve Dogs with Lymphoma
Regulatory Filings
2018-10-03 English
Oasmia Presents Positive Efficacy and Safety Data for Doxophos Vet in Treatment of Naïve Dogs with Lymphoma
Earnings Release FY 2018
2018-10-03 English
Oasmia presenterar positiva effekt- och säkerhetsdata för Doxophos Vet i studie med tidigare obehandlade hundar med lymfom
Regulatory Filings
2018-10-03 Swedish
Major Shareholding Notification 2018
Major Shareholding Notification
2018-10-01 English
Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)
Share Issue/Capital Change
2018-09-30 English
Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2018-09-30 English
Ändring av antalet aktier och röster i Oasmia Pharmaceutical AB (publ)
Share Issue/Capital Change
2018-09-30 Swedish
Major Shareholding Notification 2018
Major Shareholding Notification
2018-09-27 English
Annual General Meeting of Oasmia Pharmaceutical AB (publ) held on 25 September 2018
AGM Information
2018-09-25 English
Annual General Meeting of Oasmia Pharmaceutical AB (publ) held on 25 September 2018
AGM Information
2018-09-25 English
Årsstämma i Oasmia Pharmaceutical AB (publ) den 25 september 2018
AGM Information
2018-09-25 Swedish
Oasmia har erhållit positiv utlåtande från CHMP avseende Apealea® (paklitaxel micellär) i EU
Regulatory Filings
2018-09-21 Swedish
Oasmia Pharmaceutical Receives Positive CHMP Opinion for Apealea® (paclitaxel micellar) in the European Union
Regulatory Filings
2018-09-21 English
Update regarding the Market Authorization Application of Apealea in the European Union
Legal Proceedings Report
2018-09-18 English
Uppdatering beträffande Apealeas marknadsansökan hos EMA
Regulatory Filings
2018-09-18 Swedish
Oasmia completes a private placement of new convertible instruments in the amount SEK 35.2 million
Capital/Financing Update
2018-09-07 English
Oasmia genomför emission av konvertibler om 35,2 miljoner kronor
Capital/Financing Update
2018-09-07 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Q2 2018
2018-08-31 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Q1 2018
2018-08-31 English
Notification from Oasmia Pharmaceutical AB
Capital/Financing Update
2018-08-30 English
Notis från Oasmia Pharmaceutical AB
Capital/Financing Update
2018-08-30 Swedish
Audit Report / Information 2018
Audit Report / Information FY 2018
2018-08-24 Swedish
Annual Report 2018
Annual Report FY 2018
2018-08-24 English
Notice of Annual General Meeting in Oasmia Pharmaceutical AB
AGM Information
2018-08-24 English
KALLELSE TILL ÅRSSTÄMMA I OASMIA PHARMACEUTICAL AB
AGM Information
2018-08-24 Swedish
Notis från Oasmia Pharmaceutical AB
Capital/Financing Update
2018-08-01 Swedish
Notification from Oasmia Pharmaceutical AB
Capital/Financing Update
2018-08-01 English
Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)
Share Issue/Capital Change
2018-07-31 English
Ändring av antalet aktier och röster i Oasmia Pharmaceutical AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2018-07-31 Swedish
Status of the Market Authorisation Application of Apealea in the European Union
Legal Proceedings Report
2018-07-27 English
Status beträffande Apealeas marknadsansökan hos EMA
Legal Proceedings Report
2018-07-27 Swedish
Earnings Release 2018
Earnings Release Q4 2018
2018-06-08 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Q4 2018
2018-06-08 English
Resultat från Oasmia Pharmaceuticals fas III-studie har presenterats vid ASCOs årliga möte
Regulatory Filings
2018-06-05 Swedish
Results from Oasmia Pharmaceutical’s phase III study have been presented at ASCO annual meeting
Earnings Release FY 2018
2018-06-05 English
Nexttobe förlänger lån till Oasmia Pharmaceutical
Capital/Financing Update
2018-05-30 Swedish
Nexttobe Extends Loan to Oasmia Pharmaceutical
Capital/Financing Update
2018-05-30 English
Oasmia Pharmaceutical slutför spin-off av veterinära tillgångar till det amerikanska dotterbolaget AdvaVet, Inc.
Regulatory Filings
2018-05-21 Swedish
Oasmia Pharmaceutical Completes Spin-off of Veterinary Oncology Assets to Wholly Owned US Subsidiary, AdvaVet, Inc.
M&A Activity
2018-05-21 English
Resultat från Oasmia Pharmaceuticals fas III-studie presenteras vid ASCOs årliga möte i juni
Regulatory Filings
2018-05-17 Swedish
Results from Oasmia Pharmaceutical’s phase III study will be presented at ASCO annual meeting in June
Regulatory Filings
2018-05-17 English
Notification from Oasmia Pharmaceutical
Capital/Financing Update
2018-05-16 English
Notis från Oasmia Pharmaceutical AB
Capital/Financing Update
2018-05-16 Swedish
Notification from Oasmia Pharmaceutical AB
Regulatory Filings
2018-05-08 English
Notis från Oasmia Pharmaceutical AB
Legal Proceedings Report
2018-05-08 Swedish
Notis från Oasmia Pharmaceutical AB
Capital/Financing Update
2018-05-02 Swedish
Notification from Oasmia Pharmaceutical AB
Capital/Financing Update
2018-05-02 English
Notis från Oasmia Pharmaceutical AB
Regulatory Filings
2018-04-24 Swedish
Notification from Oasmia Pharmaceutical AB
Regulatory Filings
2018-04-24 English
Oasmia has completed a private placement of new convertible instruments in a total amount of SEK 26,000,000
Capital/Financing Update
2018-04-19 English
Oasmia har genomfört en riktad emission av konvertibler om totalt 26 000 000 kronor
Capital/Financing Update
2018-04-19 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report 9M 2018
2018-03-02 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report 9M 2018
2018-03-02 English
Oasmia Pharmaceutical’s Docecal program achieves significant development milestone
Regulatory Filings
2018-02-19 English
Oasmia Pharmaceuticals Docecal program uppnår viktig milstolpe
Regulatory Filings
2018-02-19 Swedish
Oasmia Pharmaceutical AB genomför riktad emission av teckningsoptioner
Share Issue/Capital Change
2018-01-24 Swedish
Directed issue of warrants in Oasmia Pharmaceutical AB
Share Issue/Capital Change
2018-01-24 English
Oasmia säkerställer lån om 108 MSEK
Capital/Financing Update
2018-01-02 Swedish
Oasmia Pharmaceutical Secures Financing of 108 MSEK
Capital/Financing Update
2018-01-02 English